SNS-595 potentiates the *in vivo* anti-tumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts.

Jeffrey Kumer, Jennifer Arbitrario, Jeffrey Jones, Nirupama Henjarapura, Ute Hoch, Jeffrey Silverman, Anthony Howlett and Caroline Scatena. Sunesis Pharmaceuticals, Inc. South San Francisco, CA 94080

**ABSTRACT #659**

Vehicle 2250 SNS-595: 10 mg/kg + carbo: 75 mg/kg + cisplatin: 5 mg/kg Individually and in combination, SNS-595 demonstrated significant *in vivo* antitumor activity in a panel of *in vivo* models. Monotherapy with SNS-595 was well tolerated and produced significant tumor growth delay in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and ovarian cancer models. In the H460 NSCLC model, administration of SNS-595 (10 mg/kg IV qw x 5) in combination with carboplatin at 75% of its maximum tolerated dose (MTD) (75 mg/kg IP qw x 3) resulted in a TGI of 64% compared to 49% with carboplatin alone. In the BxPC-3 pancreatic cancer model, SNS-595 combined with gemcitabine significantly delays tumor growth and enhances survival of mice bearing H460 NSCLC tumors compared to single agent carboplatin.

**METHODS**

**STUDY DESIGN**

- **Cal-Lane**
  - All experiments were performed in accordance with protocols approved by the Sunesis Pharmaceuticals, Inc. Institutional Animal Care and Use Committees and in accordance with Federal Regulations.

**COMBINATION STUDIES**

- Combinations of SNS-595 with carboplatin, cisplatin, and gemcitabine demonstrate potent anti-tumor activity resulting in increased long term survival of mice bearing xenograft tumors.

- **METHODS**

- **STUDY DESIGN**

- **SNS-595 and CARBOPlatin INHIBIT NSCLC XENOGRAFT GROWTH**

- **SNS-595 and GEMCITABINE SIGNIFICANTLY INHIBIT PANCREATIC CANCER XENOGRAFT GROWTH**

- **SNS-595 and GEMCITABINE SIGNIFICANTLY INHIBIT OVARIAN CANCER XENOGRAFT GROWTH**

- **DATA SHOWN**

- **Summary**

- **SNS-595** combined with gemcitabine significantly delays tumor growth and enhances survival of mice bearing H460 NSCLC tumors compared to single agent gemcitabine.